XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

XOMA Corporation

XOMA Royalty is a biotech royalty aggregator that assists biotech companies in improving human health by acquiring the economic rights to future milestone and royalty payments related to partnered pre-commercial clinical candidates.

XOMA Royalty

XOMA Royalty | 5,133 followers on LinkedIn. We are a biotechnology royalty aggregator playing a distinctive role to help biotech companies achieve their goals. | XOMA Royalty Corporation is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health.  XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies.  When XOMA acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes.

Barbara Kosacz

Thomas Burns

Joyce Chan

Today we added 60-plus assets across 30 partners to the XOMA Royalty portfolio. Our strategic transaction with Twist Bioscience provides XOMA Royalty with a 50% economic interest in the royalties and milestones originating from Twist Biopharma Solutions. With 6 commercial assets and 7 in Phase 3 development today, we have been working to build and scale XOMA Royalty’s future commercial asset portfolio. Brad Sitko stated, “This transaction reinforces our commitment to a disciplined capital deployment strategy and showcases our ability to create bespoke royalty capital solutions to meet the unique needs of our partners.” XOMA Royalty’s portfolio now has over 100 assets with milestone potential over $1 billion. You can read our press release here https://bit.ly/3BUXsPl #Royalty #Royalties #Monetization #Milestones #Strategy #Aquisition #Portfolio #Growth #Scale #RoyaltyCapitalSolutions

XOMA Royalty is pleased to participate in the Orrick, Herrington & Sutcliffe LLP and CBRE Global Workplace Solutions (GWS) / CBRE Life Sciences Alternative Funding Summit on Monday, October 7. If you would like to meet with members of our business development team, please contact Brad Sitko or Nicholas A. Cole . #Royalty #Royalties #RoyaltyMonetization #AltFinance

Holders of XOMA Royalty’s perpetual preferred shares XOMAP and XOMAO on October 3, 2024, should anticipate receiving their dividend on October 15, 2024. Details can be found in our September 23rd press release https://bit.ly/4diXOwl #Dividends #DividendPayments #DividendStocks #PerpetualPreferred #XOMAP #XOMAO #Royalty

FDA’s approval of MIPLYFFA™ (arimoclomol) on Friday, September 20, was a watershed moment for the Niemann-Pick disease type C (NPC) community and for Zevra Therapeutics . MIPLYFFA™ is the first FDA-approved therapy for use in patients 2 years of age and older with this ultra-rare, relentlessly progressive, degenerative, and potentially fatal disease. XOMA Royalty is entitled to receive a mid-single digit royalty on MIPLYFFA™ sales and up to $52.6 million in milestone payments. Our press release can be found here https://bit.ly/3XUjYk7 . More detailed information on MIPLYFFA™ can be found in Zevra’s press release which is available here https://bit.ly/3XS9d1t . #NPC #NiemannPick #MIPLYFFA #arimoclomol #Royalties #Royalty #Milestones #NewDrugApproval #RareDisease

Owen Hughes and Brad Sitko had an engaging conversation with Eric Schmidt at the 2024 Cantor Fitzgerald Global Healthcare Conference. You can listen to the replay here - https://bit.ly/3TzLgJH #CantorHCC #Royalties #Royalty #Monetization #LifeSciences #Acquisition #Portfolio

Owen Hughes and Brad Sitko will present XOMA Royalty’s latest updates during the H.C. Wainwright & Co., LLC and Cantor Fitzgerald conferences. We look forward to seeing you there! https://lnkd.in/gd3YyFnJ #HCWainwrightGlobal #CantorHCC #Royalties #Royalty #Monetization #LifeSciences #Acquisition #Portfolio

Yesterday we announced XOMA’s 2Q2024 financial results, which included total cash receipts of $22.6 million, inclusive of royalty income and milestones from two partners. Since March, there have been several significant advancements within our royalty and milestone portfolio that are the result of our partners’ commitments to bring new therapies to patients in need of treatment options. Details are available in our press release, which you can access here https://bit.ly/4dCPsjw #Royalty #Royalties #Milestones #OJEMDA #arimoclomol #RZ358 #Ersodetug #ITP #XACIATO #DaréBio #Ovaprene #SildenafilCream #Acquisition

On Friday, the newly convened FDA Genetic Metabolic Advisory Committee (GeMDAC) reviewed the data supporting the #arimoclomol NDA filing. At the conclusion of the meeting, the GeMDAC voted favorably that the data support the use of arimoclomol in patients with #NiemannPick disease type C. We look forward to the FDA’s decision on Zevra Therapeutics ’s NDA filing in September. XOMA Royalty acquired over $52M in potential milestones and a mid-single digit royalty interest in arimoclomol from LadRx in June 2023. #NPC #Zevra #Royalty #Royalties #Milestones #RareDisease

XOMA Royalty is widely recognized as a leading royalty aggregator within the biotech ecosystem, creating bespoke royalty capital solutions. To reflect this business model shift dating back to 2017, and to continue to recognize XOMA's legacy biotech R&D activities that contributed to our 70+ asset portfolio, we have officially changed our name to XOMA Royalty Corporation. #XOMARoyalty #Royalty #Milestones #RoyaltyAggregator #NameChange #NewChapter #XOMA

Sildenafil Cream 3.6% was one of the three royalty interests we acquired at the end of April in a royalty transaction with Daré Bioscience, Inc. The Phase 2b study results were published in the premiere publication for OBGYNs, Obstetrics & Gynecology. We look forward to Daré’s progress toward initiating a Phase 3 study with this first-in-category asset for female sexual arousal disorder (FSAD). #SildenafilCream #FSAD #FemaleSexualArousalDisorder #royalty #RoyaltyInterest #RoyaltyAcquisition #ClinicalData #ObstetricsandGynecology #AmericanCollegeofObstetriciansandGynecologists #ACOG

Metric
Company Name	XOMA Corporation
Symbol	XOMA
MSH ID	COM:XOMA
Market	STOCKS
Sector	Healthcare
Industry	Biotechnology
Country	US
Stage
Employee Count	13
Website	xoma.com
LinkedIn	xoma
Founders

Metric
Market Cap	298.88M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	4.76M
Revenue (LTM)
Revenue (NTM)
Gross Profit	3.86M
EBITDA	-20.99M
Operating Income	-21.89M
Net Income	-40.83M
EPS	-3.56
Diluted EPS	-3.56
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.97
Operating Profit Margin	-1.28
EBITDA Margin	-4.41
Net Profit Margin	-1.20
Return on Equity	-0.19
Return on Assets	-0.07
Return on Capital Employed	-0.09

COM:XOMA

XOMA Royalty

Last Close

30.07

22/11 21:00

Market Cap

298.88M

Beta: -

Volume Today

40.01K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-6.59
P/B Ratio	2.15
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	63.09
EV Multiple	-11.63

Metric
Days Sales Outstanding	3.56
Days Payables Outstanding	345.09
Days Inventory Outstanding	0.00
Operating Cycle	1.17K
Cash Conversion Cycle	902.08
Asset Turnover	0.06

Metric
Operating Cash Flow	-18.16M
Free Cash Flow	-32.83M
Cash Flow to Debt	-0.07
Operating Cash Flow/Sales	-0.58
Free Cash Flow Yield	-0.08

Metric
Cash & Equivalents	153.45M
Accounts Receivable	-1.00M
Inventory
Goodwill
Debt to Capitalization	0.59
Debt to Assets	0.03
Current Ratio	3.34
Quick Ratio	9.45

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	1.69
R&D to Revenue	0.03
SG&A to Revenue	5.87